Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135521 | 0.74 | — | — | |
| SCHEMBL16115775 | 0.68 | PLA2G2A (0.34) | — | |
| SCHEMBL17465181 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL16135522 | 0.65 | UGT2B7 (0.38) | — | |
| SCHEMBL16115428 | 0.65 | NFE2L2 (0.52) | NFE2L2 | |
| SCHEMBL19336678 | 0.63 | — | — | |
| SCHEMBL17465174 | 0.63 | — | — | |
| SCHEMBL8392577 | 0.62 | NFE2L2 (0.35) | NFE2L2 | |
| SCHEMBL14364127 | 0.61 | HTT (0.35) | — | |
| SCHEMBL16114912 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2978748-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2978748-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | Pfizer Ireland Pharmaceuticals (IE) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | GABRE, GABRG1, GABRG2 | NFE2L2 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.